Bioengineering Center, Grape King Bio Report issue

For profit
Founded: Shanghai China (1991)

Organization Overview

First Clinical Trial
2020
NCT04428983
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bioengineering Center, Grape King Bio

Active Ingredients

Drugs in Other Trials (1)

hericium erinaceus mycelia (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 1